Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...
Novo Nordisk has bolstered its pipeline by paying $340 million upfront for rights to an Omeros Corp drug with potential ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at ...
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...
Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback